Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pertuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intrathecal
01
Overview
This combination therapy consists of two HER2-targeted monoclonal antibodies, pertuzumab and trastuzumab, administered intrathecally for the treatment of HER2-positive breast cancer brain metastases. Pertuzumab (Perjeta) binds to the dimerization domain (domain II) of the HER2 protein, preventing it from pairing with other HER family members, while trastuzumab (Herceptin) binds to domain IV. Together, they provide a more comprehensive blockade of HER2 signaling and promote antibody-dependent cellular cytotoxicity (ADCC). This specific investigation, led by Dr. Kimberly Blackwell at Duke University, explores the safety and efficacy of direct cerebrospinal fluid delivery via lumbar puncture to overcome the limited blood-brain barrier penetration of these biologics when administered intravenously.
- Brand names
- PerjetaHerceptin
- Other names
- Intrathecal pertuzumab and trastuzumab
02
Targets
HER2 ECD II (Human epidermal growth factor receptor 2 domain II)
Beyond the preview
Go deeper on pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pertuzumab + trastuzumab.